Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A+C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study.

Fausto Roila,Enzo Ballatori,Alessandra Fabi,Sonia Fatigoni,Silvana Chiara,Maria Teresa Ionta,Michele Aieta,Mario Clerico,Maria Angela Palladino,Monica Indelli,Ornella Garrone,S Bustreo,Benedetta Ruggeri

Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A+C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study.

2017

Fausto Roila
Enzo Ballatori
Alessandra Fabi
Sonia Fatigoni
Silvana Chiara
Maria Teresa Ionta
Michele Aieta
Mario Clerico
Maria Angela Palladino
Monica Indelli
Ornella Garrone
S Bustreo
Benedetta Ruggeri

9614 Background: A combination of AP + a 5-HT3 receptor antagonist + D and AP alone is recommended, respectively, for the prophylaxis of acute and delayed emesis induced by A+C CT in breast cancer ...

Keywords:

Aprepitant
Breast cancer
Pathology
Dexamethasone
Receptor antagonist
Oncology
Randomized controlled trial
Chemotherapy
Internal medicine
Cyclophosphamide
Medicine
Gastroenterology
double blind

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations